NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

A couple leaps here. I don't know they are necessarily correct leaps, because not founded upon anything other than guesswork.

Nonetheless PFS is still the Primary Endpoint and OS is still the Secondary Endpoint. Although if the long tail exists and it is statistically significant, meaning there are clear separations between the some comparable groups, and FDA will have to approve the vaccine because of that, the best interest for the company is that PFS endpoint is better approved statistically significant. Besides, nobody can guarantee that the long tail will be a clear cut without unblinding.

All these have hinged on the SAP saga we have all experienced for so long.... -- Dan

Not certain the things you wrote that I highlighted in red are correct.